Summary

Eligibility
for people ages 25-65 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
Suneil Koliwad, MD,PhD
Photo of Suneil Koliwad
Suneil Koliwad

Description

Summary

Obesity affects over one third of US adults (>72 million, with BMI ≥30 kg/m2), and the proportion of US adults with BMI ≥40 kg/m2 has doubled in the last 20 years. Obesity is associated with increased mortality through its linkage to comorbidities including diabetes, hypertension, dyslipidemia, osteoarthritis, sleep apnea and psychosocial disturbances. Given its prevalence, impact on morbidity and mortality, and economic cost, limiting the spread of obesity and its consequences is one of the most important problems of our time. In this proposed study, investigators will recruit subjects from a wide range of body mass index (BMI), ethnicity and Diabetes risk to collect data and blood, stool and adipose tissue samples in the San Francisco bay area.

Official Title

Development of a Multi-Ethnic, Multimodal Obesity Cohort

Details

The Inflammation, Diabetes, Ethnicity and Obesity (IDEO) cohort is recruiting 200 individuals from various ethnicities, covering a spectrum of weight and Diabetes risk. The study healthy lean, overweight and obese subjects and people who are slated to undergo any type of bariatric surgery for obesity or any other type of abdominal surgery at UCSF.

Keywords

Obesity Diabetes Mellitus ethnicity inflammation

Eligibility

You can join if…

Open to people ages 25-65

  • Subjects will be between the ages of 25-65 years. These cutoffs are designed to allow inclusion of postmenopausal women, and younger/more active patients who are increasingly undergoing bariatric surgery.
  • Patients with either diabetes type 2 or the metabolic syndrome will be included in the cohort.

You CAN'T join if...

  • Subjects with chronic kidney disease (> stage 4)
  • Autoimmune/inflammatory disease (e.g., Lupus, Ulcerative Colitis, etc.)
  • Unstable angina, New York (NY) class III or IV congestive heart failure or myocardial infarction within 3 months of entry
  • Clinically significant liver disease (e.g. Cirrhosis or liver failure)
  • Weight > 450 pounds (DXA scan weight limit)
  • History of organ transplant
  • Treatment with chemotherapy or radiation therapy at the time of enrollment in study.
  • Poorly controlled asthma (subjects requiring inhaled glucocorticoids and/or oral glucocorticoids)
  • Current nasal corticosteroid use (within the past month)
  • Excessive alcohol or substance abuse
  • Current use of anabolic steroids or testosterone for bodybuilding purposes. Testosterone use is permitted if prescribed for hypogonadism and dose stable for the past 6 months.
  • Patients actively enrolled in interventional trials involving investigational agents
  • Known HIV infection and/or AIDS
  • Pregnant or breast-feeding women
  • Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.

Location

  • University of California San Francisco accepting new patients
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Suneil Koliwad, MD,PhD
    Dr. Suneil Koliwad is an Endocrinologist and an Expert in Diabetes, Obesity, and Metabolism. His lab focuses on the intersection of nutrition, inflammation, and metabolic tissue function in the context of normal physiology, and diseases such as obesity, diabetes, fatty liver disease, and in the course of aging.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
Links
Koliwad Lab
ID
NCT03022682
Study Type
Observational
Last Updated